NEW YORK, Dec. 4, 2017 /PRNewswire/ -- In keeping with the commitment to dynamically provide members with timely information,WallStEquities.com has issued free tailored Stock Review on IRWD, NBIX, COLL, and MYL which is a click away at www.wallstequities.com/registration. The Generic Drugs market can be segmented into biosimilars, simple generic, and super generic. Based
Massachusetts headquartered Ironwood Pharmaceuticals Inc.'s shares rose 0.29%, finishing last Friday's session at $17.32. A total volume of 1.10 million shares was traded. Over the last month and the previous three months, the stock has advanced 16.55% and 7.18%, respectively. Furthermore, the Company's shares have gained 13.28% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 10.76% and 3.89%, respectively. Additionally, shares of Ironwood Pharma have a Relative Strength Index (RSI) of 69.43.
On November 28th, 2017, Ironwood Pharmaceuticals announced the appointment of William Huyett as COO and the promotion of Gina Consylman to Senior Vice President and CFO. Mr. Huyett brings to the Company extensive experience in corporate strategy, capital allocation, finance, product development/commercialization, and corporate leadership in the Life Sciences industry and many other business sectors. Ms. Consylman currently provides the Company oversight of its finance, planning, accounting, tax, treasury, and insurance functions. Free Access to today's research report on IRWD at:
On Friday, shares in California headquartered Neurocrine Biosciences Inc. ended the session 2.38% higher at $73.60. The stock recorded a trading volume of 916,513 shares. The Company's shares have surged 20.79% in the last month, 29.10% in the previous three months, and 90.18% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 12.45% and 38.91%, respectively. Moreover, shares of Neurocrine Biosciences have an RSI of 60.51.
On November 29th, 2017, Neurocrine Biosciences announced that new, long-term data from the open-label KINECT 4 Phase-III study of INGREZZA® (valbenazine) capsules, the first FDA-approved treatment for adults with tardive dyskinesia (TD), will be presented at the Hot Topics Session at the American College of Neuropsychopharmacology (ACNP) Annual Meeting, which is being held from December 03rd, 2017, to December 07th, 2017 in Palm Springs, California. TD is characterized by uncontrollable, abnormal, and repetitive movements of the trunk, extremities, and/or face. Find your free research report NBIX at:
Massachusetts headquartered Collegium Pharmaceutical Inc.'s stock declined 1.51%, to close the day at $17.00 with a total trading volume of 677,384 shares. The Company's shares have advanced 78.01% in the last one month, 70.17% over the previous three months, and 9.18% since the start of this year. The stock is trading 38.17% and 48.21% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Collegium Pharma have an RSI of 63.13.
On November 07th, 2017, Collegium Pharmaceutical announced that the US FDA approved its Supplemental New Drug Application to enhance the label for Xtampza® ER (oxycodone extended-release), an abuse-deterrent, extended-release opioid, for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Sign up today for the free report on COLL at:
Shares in UK-based Mylan N.V. recorded a trading volume of 7.80 million shares, which was above their three months average volume of 6.10 million shares. The stock ended at $38.12, jumping 4.35% from the last trading session. The Company's shares have gained 3.45% in the past month and 20.75% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 4.37% and 1.97%, respectively. Furthermore, shares of Mylan have an RSI of 55.67.
On November 07th, 2017, research firm RBC Capital Markets reiterated its 'Sector Perform' rating on the Company's stock with an increase of the target price from $32 a share to $37 a share.
On November 30th, 2017, Mylan announced that the EMA has accepted for review the Company's Marketing Authorization Applications for proposed biosimilar trastuzumab and proposed biosimilar pegfilgrastim. Trastuzumab is used to treat certain HER2-positive breast and gastric cancers. Pegfilgrastim is used to reduce the duration of neutropenia (low count of neutrophils, a type of white blood cells) and the incidence of fever associated with neutropenia in adult patients treated with chemotherapy in certain types of cancer. Access the free report on MYL at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly.If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/free-research-reports-on-these-generic-drugs-stocks----ironwood-pharma-neurocrine-biosciences-collegium-pharma-and-mylan-300565759.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Sleep disorders are collectively known as ''Somnipathy.'' There are over 70 different medically ...
Unintended pregnancies are very common these days, and so one in about four pregnant women go for ...
Dizziness is a feeling of being faint or unsteady whereas Vertigo is a feeling that you or your ...View All